The surgical weight-loss landscape faces a pivotal question as GLP-1 receptor agonists like semaglutide and tirzepatide become mainstream obesity treatments: should patients use these medications before undergoing bariatric surgery? This comprehensive analysis of 5,461 patients across 10 studies reveals a nuanced answer that challenges simple assumptions about combining pharmaceutical and surgical interventions.
Patients receiving preoperative GLP-1 therapy achieved modest additional weight reduction compared to controls—approximately 4.87 kg versus 3.84 kg before surgery. However, this early advantage did not translate into superior long-term outcomes. Post-surgical total weight loss percentages showed no significant difference between groups, and complication rates remained statistically similar. Notably, the metabolic benefits many clinicians hoped for—improved diabetes remission rates and better glycemic control—failed to materialize in this pooled analysis.
These findings illuminate a critical gap in our understanding of pharmaceutical-surgical synergy. While GLP-1 medications excel as standalone obesity treatments, their role as surgical preparation appears limited to modest preoperative conditioning. The lack of enhanced long-term weight loss suggests that bariatric surgery's mechanisms—hormonal restructuring, gastric restriction, and metabolic reprogramming—may overshadow any preparatory pharmaceutical effects. For the 260,000 Americans undergoing bariatric procedures annually, this research indicates that mandatory preoperative GLP-1 protocols may offer marginal clinical benefit despite significant cost. The field now needs longer-term studies examining whether sustained post-surgical GLP-1 use might optimize outcomes where preoperative administration falls short.